REFERENCES

Anderson, P., M. E. Pichichero, and R. A. Insel. 1985. Immunization of 2-month-old infants with protein-coupled oligosaccharides derived from the capsule of hemophilus-influenzae type-B. Journal of Pediatrics 107(3):346-351.

Apicella, M. A. 2010. Neisseria meningitidis. In Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 7th ed. 2 vols. Vol. 2, edited by G. L. Mandell, J. E. Bennett, and R. Dolin. Philadelphia, PA: Churchill Livingstone Elsevier. Pp. 2737-2751.

Ball, R., M. M. Braun, G. T. Mootrey, S. Ellenberg, S. Rastogi, C. Krueger, R. Wise, M. Niu, D. Davis, F. Varricchio, P. Perucci, T. DuVernoy, R. Chen, P. Haber, V. Pool, W. Wattigney, T. Strine, R. Pless, V. Caserta, and G. Evans. 2001. Safety data on meningococcal polysaccharide vaccine from the Vaccine Adverse Event Reporting System. Clinical Infectious Diseases 32(9):1273-1280.

Bentsi-Enchill, A. D., I. Zongo, S. Khamassi, R. Pless, R. Thombiano, S. Tiendrebeogo, C. B. Nelson, and P. Duclos. 2007. Monitoring of adverse events during the 2003 mass vaccination campaign with a trivalent meningococcal A/C/W135 polysaccharide vaccine in Burkina Faso. Vaccine 25(Suppl. 1):A72-A78.

CDC (Centers for Disease Control and Prevention). 2005. Prevention and control of meningococcal disease—recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity & Mortality Weekly Report 54(RR7):1-10, 11-21.

CDC. 2010. National, state, and local area vaccination coverage among adolescents aged 13-17 years—United States, 2009. Morbidity & Mortality Weekly Report 59(32):1018-1023.

Datie, A. M., B. Assi, P. Cowppli-Bony, E. Aka-Diarra, T. Sonan-Douayoua, F. Boa Yapo, and E. B. Kouassi. 2003. Recurrent polyradiculoneuropathies following vaccination in Côte d’Ivoire [in French]. African Journal of Neurological Sciences 22(2).

De Wals, P., G. Deceuninck, R. M. Boucher, and M. Ouakki. 2008. Risk of Guillain-Barré syndrome following serogroup C meningococcal conjugate vaccine in Quebec, Canada. Clinical Infectious Diseases 46(8):e75-e77.

Ferry, N. S., and A. H. Steele. 1935. Active immunization with meningococcus toxin. Journal of the American Medical Association 104:983-984.

Gates, F. L. 1918. A report on antimeningitis vaccination and observations on agglutinins in the blood of chronic meningococcus carriers. Journal of Experimental Medicine 28(4):449-474.

Gotschlich, E. C., T. Y. Liu, and M. S. Artenstein. 1969. Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides. Journal of Experimental Medicine 129(6):1349-1365.

Gotschlich, E. C., M. Rey, R. Triau, and K. J. Sparks. 1972. Quantitative determination of human immune-response to immunization with meningococcal vaccines. Journal of Clinical Investigation 51(1):89-96.

Granoff, D. M., L. H. Harrison, and R. Borrow. 2008. Chapter 19. Meningococcal vaccines. In Vaccines, edited by S. A. Plotkin, W. A. Orenstein, and P. A. Offit. Philadelphia, PA: Saunders/Elsevier. Pp. 399-432.

Kabat, E. A., and A. E. Bezer. 1958. The effect of variation in molecular weight on the antigenicity of dextran in man. Archives of Biochemistry and Biophysics 78(2):306-318.

Kabat, E. A., H. Kaiser, and H. Sikorski. 1944. Preparation of the type-specific polysaccharide of the type I meningococcus and a study of its effectiveness as an antigen in human beings. Journal of Experimental Medicine 80(4):299-307.

Kelly, D. F., A. J. Pollard, and E. R. Moxon. 2005. Immunological memory—the role of B cells in long-term protection against invasive bacterial pathogens. Journal of the American Medical Association 294(23):3019-3023.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement